H. Lee Moffitt Cancer Center & Research Institute

Physician, Faculty, and Staff

Jhanelle Gray, MD

Jhanelle Gray, MD

Faculty Rank:

Assistant Member

Titles:

Department/Program Affiliations:

  • Breast  
  • Experimental Therapeutics  
  • Thoracic Oncology  

Primary Address:

H. Lee Moffitt Cancer Center &
Research Institute
12902 Magnolia Drive
Tampa, FL 33612

Consultation/Referral Phone:

(813) 745-3050

USF Affiliations/College Department:

  • Medicine / Oncologic Sciences

University Academic Rank:

Assistant Professor

For corrections, please e-mail a request

Printer friendly version
Printer friendly version (including publications)

Jhanelle Gray, MD

Education & Training:

  • MD, Wiell Medical College of Cornell University, New York, NY, 2001 - Medical Doctor
  • Residency, The New York Presbyterian Hospital, New York, NY, 2004
  • Fellowship, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, 2007 - Hematology/Oncology

General Board Certification / SubSpecialty:

  • Internal Medicine
  • Internal Medicine / Medical Oncology
  • Internal Medicine / Hematology

For corrections, please e-mail a request

Printer friendly version
Printer friendly version (including publications)

Jhanelle Gray, MD

Research Interests:

My research interests include the chemoprevention of lung cancer and the targeting of treatment based on genetics in breast cancer patients.


Clinical Interests:

My clinical interests focus upon thoracic and breast oncology.

For corrections, please e-mail a request

Printer friendly version
Printer friendly version (including publications)

Jhanelle Gray, MD

Publications:

  1. Haura EB, Tanvetyanon T, Chiappori A, Williams C, Simon G, Antonia S, Gray J, Litschauer S, Tetteh L, Neuger A, Song L, Rawal B, Schell MJ, Bepler G. Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer. J Clin Oncol. 2010 Mar;28(8):1387-1394. Pubmedid: 20142592.   Pubmed ID: 20142592

  2. Lee MC, Gray J, Han HS, Plosker S. Fertility and reproductive considerations in premenopausal patients with breast cancer. Cancer Control. 2010 Jul;17(3):162-172. Pubmedid: 20664513.   Pubmed ID: 20664513

  3. Gray J, Sommers E, Alvelo-Rivera M, Robinson L, Bepler G. Neoadjuvant chemotherapy for resectable non-small-cell lung cancer. Oncology (Williston Park). 2009 Sep;23(10):879-886. Pubmedid: 19839429.   Pubmed ID: 19839429

  4. Gray J, Alberts W, Bepler G. Statins and lung cancer risk. Chest. 2007 May;131(5):1274-1275. Pubmedid: 17494775.   Pubmed ID: 17494775

  5. Gray J, Mao J, Szabo E, Kelley M, Kurie J, Bepler G. Lung cancer chemoprevention: ACCP evidence-based clinical practice guidelines (2nd Edition). Chest. 2007 Sep;132(3 Suppl):56S-68S. Pubmedid: 17873160.   Pubmed ID: 17873160

  6. Gray J, Murren J, Sharma A, Kelley S, Detterbeck F, Bepler G. Perforated viscus in a patient with non-small cell lung cancer receiving bevacizumab. J Thorac Oncol. 2007 Jun;2(6):571-573. Pubmedid: 17545855.   Pubmed ID: 17545855

  7. Nanjundan M, Nakayama Y, Cheng K, Lahad J, Liu J, Lu K, Kuo W, Smith-McCuneK, Fishman D, Gray J, Mills G. Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancer. Cancer Res. 2007 Apr;67(7):3074-3084. Pubmedid: 17409414.   Pubmed ID: 17409414

  8. Lancaster J, Carney M, Gray J, Myring J, Gumbs C, Sampson J, Wheeler D, France E, Wiseman R, Harper P, Futreal P. BRCA1 and BRCA2 in breast cancer families from Wales: moderate mutation frequency and two recurrent mutations in BRCA1. Br J Cancer. 1998 Dec;78(11):1417-1420. Pubmedid: 9836472 .   Pubmed ID: 9836472

Jhanelle Gray, MD

Below is a list of active grants where the faculty member is the Principal Investigator. Grants are sorted by sponsor and then sorted by start date, with the more recent grant shown first.

Phase I Dose Escalation Study of LY2090314 in Pts with Adv or Metastatic CA with Pemetrexed/Carboplatin
Sponsor: Eli Lilly & Company
Project Dates: September 6, 2007 to September 5, 2010
Annual Direct Cost: $85,583
Annual Total Cost: $111,256
Project Total: $308,305

Phase I Study of IPI 504 and Docetaxel in Pts with ADV Solid Tumors
Sponsor: Infinity Pharmaceutical
Project Dates: December 26, 2009 to December 25, 2011
Earned to Date: $75,880

IPI-504 in Relapsed and/or Refractory Stage IIIb or Stage IV NSCLC Patients
Sponsor: Infinity Pharmaceutical
Project Dates: December 4, 2008 to December 3, 2010
Earned to Date: $124,132

Physician/Faculty  Contact Form

© Copyright 1996 - 2010 H. Lee Moffitt Cancer Center & Research Institute